Системные гипертензии (Jan 2016)

The possibility of perindopril in angioprotective in patients with metabolic syndrome after combination therapy with a thiazide diuretic

  • Nedogoda S.V.,
  • Smirnova V.O.,
  • Khripaeva V.Yu.

DOI
https://doi.org/10.26442/2075-082X_13.1.30-33
Journal volume & issue
Vol. 13, no. 1
pp. 30 – 33

Abstract

Read online

Aim. To assess the possibility of monotherapy with perindopril after transferring from combination therapy with losartan and hydrochlorothiazide with respect to correction of the anthropometric, metabolic parameters, premature vascular aging and vascular elasticity in patients with metabolic syndrome.  Material and methods. Held open prospective controlled study of 50 patients with metabolic syndrome (IDF, 2005), which reached BP<140/90 mm Hg during three months of therapy with losartan (50 mg) + hydrochlorothiazide (12.5 mg) with conversion to monotherapy with perindopril 10 mg for 12 weeks. Patients were evaluated anthropometric and metabolic parameters, levels of adipokines, and indices of vascular elasticity and age was estimated on the date of the transfer with casinadirosa combination monotherapy with perindopril and after 12 weeks thereafter.  Results. The results of the study demonstrated the possibility of a transfer with combination antihypertensive therapy monotherapy perindopril patients with metabolic syndrome that contributes to slow vascular aging, improve the elasticity of blood vessels, reduces inflammation and has a beneficial impact on adipokines.  Conclusion. When achieved BP<140/90 mm Hg on combination with a thiazide diureticpossible in patients with MS monotherapy perindopril with consequent improvement in elasticity of blood vessels and of adipokines.

Keywords